09:11 AM EDT, 10/08/2025 (MT Newswires) -- Werewolf Therapeutics ( HOWL ) said Wednesday it has received a 'fast track' designation from the US Food and Drug Administration for its invesigational potential treatment for patients with locally advanced or metastatic cutaneous melanoma, WTX-124, after standard of care immunotherapy.

The fast track designation is intended to expedite development of drugs to address a serious unmet medical need and provides for frequent interactions with the FDA, the company said.

Shares of the company were up 7.8% in recent Wednesday premarket activity.